Lupin Profit Falls 22% Despite Strong US Business Growth

has reported a mixed Q2 FY27 performance, and there's an important detail investors should not overlook. The pharmaceutical company reported a 22.2% year-on-year decline in consolidated net profit to ₹1,155 crore. However, revenue increased 11.1% to ₹7,827 crore. But here's an interesting development. Lupin launched Raltegravir Tablets USP 600 mg in the US after receiving approval from the US FDA. The company is the exclusive first-to-file applicant and is eligible for 180 days of generic drug exclusivity. Why does this matter? Generic drug exclusivity can provide a temporary competitive advantage, allowing a company to capture market share before other generic competitors enter. For Indian pharmaceutical companies, the US market is important because successful product launches can create additional revenue opportunities. However, investors should also track pricing pressure, competition and the sustainability of US business margins. For me, the interesting part of Lupin's story is the contrast between declining quarterly profit and new opportunities in the US generics market. The next few quarters will show whether new launches can translate into stronger earnings growth.